AZD0305 Trial
Phase 1/2
226
about 3.3 years
18+
9 sites in CA, GA, MA +5
What this study is about
Researchers are testing AZD0305 as a treatment for relapsed/refractory multiple myeloma. The trial will evaluate the safety, tolerability, and effectiveness of AZD0305 in adults with this condition.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD0305
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)
Secondary: Phase Ia: Duration of response (DoR), Phase Ia: Objective Response Rate (ORR), Phase Ia: Overall Survival (OS), Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC), Phase Ia: Pharmacokinetics of AZD0305: Clearance, Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax), Phase Ia: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2), Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)
Oncology